Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement

Regeneron Pharmaceuticals experienced significant downward pressure on its stock today, primarily driven by the disappointing results from a key Phase 3 clinical trial. The company announced that its trial evaluating the combination of fianlimab and cemiplimab as a first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of progression-free survival (PFS).

Although the high-dose combination showed a numerically improved median PFS compared to pembrolizumab monotherapy, this difference was not statistically significant. This clinical setback was viewed as a "worst-case scenario" by some industry analysts, as it eliminates a potentially lucrative market opportunity estimated to be worth billions. The market reaction also reflects broader concerns over Regeneron's pipeline, as this follows previous late-stage trial failures and regulatory delays for other key drugs.

In response to the trial results, several prominent analyst firms downgraded their ratings and reduced their price targets for Regeneron. For instance, Citi downgraded the stock from Buy to Neutral and lowered its price target, citing the removal of fianlimab's melanoma opportunity from its valuation models. Similarly, Leerink downgraded the stock from Outperform to Market Perform, expressing concerns about long-term earnings per share growth, potential underperformance of the flagship Eylea franchise, and increased competition from biosimilars. Other firms like Wells Fargo and RBC Capital also reduced their price targets, signaling a more cautious outlook. These analyst adjustments contributed significantly to the negative market sentiment surrounding the company.

While Regeneron also announced a strategic collaboration with Parabilis Medicines to advance novel antibody-Helicon™ conjugates, involving a substantial upfront investment and potential milestone payments, this positive corporate development was overshadowed by the clinical trial failure and subsequent analyst revisions. The convergence of a significant clinical trial miss and widespread analyst downgrades are the primary factors contributing to today's substantial share price decline.

Technically, Regeneron Pharmaceuticals Inc (REGN) shows a MACD (12,26,9) value of [-10.80], indicating a neutral signal. The RSI at 39.33 suggests neutral condition and the Williams %R at -65.47 suggests oversold condition. Please monitor closely.

Regeneron Pharmaceuticals Inc (REGN) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $14.34B, ranking 18 in the industry. The net profit is $4.50B, ranking 14 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $865.02, a high of $1057.00, and a low of $660.00.

Company Specific Risks:

• Regeneron's stock declined sharply today following the failure of an experimental drug in a late-stage clinical trial, indicating a significant setback in its pipeline and potential future revenue generation.
• The company faces increasing competitive pressures for its flagship product, Eylea HD, which accounts for 50% of its U.S. sales, compounded by affordability issues for patients and the anticipated entry of biosimilar competitors for Eylea 2mg in the second half of 2026.
• Regulatory delays from the FDA for the Eylea HD Prefilled Syringe introduce uncertainty and potential disruption to the product's market access and revenue stream.